Latest News and Press Releases

Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients

Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023

Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.

SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...

            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...